Data from Multifunctional mRNA-Based CAR T Cells Display Promising Antitumor Activity Against Glioblastoma

Data from Multifunctional mRNA-Based CAR T Cells Display Promising Antitumor Activity Against Glioblastoma

Data from Prognostic Significance of DNA Methylation Profiles at MRI Enhancing Tumor Recurrence: a Report from the EORTC 26091 TAVAREC Trial

Data from Prognostic Significance of DNA Methylation Profiles at MRI Enhancing Tumor Recurrence: a Report from the EORTC 26091 TAVAREC Trial

Data from Temozolomide and Radiotherapy versus Radiotherapy Alone in Patients with Glioblastoma, <i>IDH</i>-wildtype: <i>Post Hoc</i> Analysis of the EORTC Randomized Phase III CATNON Trial

Data from Temozolomide and Radiotherapy versus Radiotherapy Alone in Patients with Glioblastoma, <i>IDH</i>-wildtype: <i>Post Hoc</i> Analysis of the EORTC Randomized Phase III CATNON Trial

Data from The Epigenetic Evolution of Glioma Is Determined by the <i>IDH1</i> Mutation Status and Treatment Regimen

Data from The Epigenetic Evolution of Glioma Is Determined by the <i>IDH1</i> Mutation Status and Treatment Regimen

Supp Figures from The Epigenetic Evolution of Glioma Is Determined by the <i>IDH1</i> Mutation Status and Treatment Regimen

Supp Figures from The Epigenetic Evolution of Glioma Is Determined by the <i>IDH1</i> Mutation Status and Treatment Regimen

Supplemental Figures Legends from The Epigenetic Evolution of Glioma Is Determined by the <i>IDH1</i> Mutation Status and Treatment Regimen

Supplemental Figures Legends from The Epigenetic Evolution of Glioma Is Determined by the <i>IDH1</i> Mutation Status and Treatment Regimen

Supplementary Appendix from The Epigenetic Evolution of Glioma Is Determined by the <i>IDH1</i> Mutation Status and Treatment Regimen

Supplementary Appendix from The Epigenetic Evolution of Glioma Is Determined by the <i>IDH1</i> Mutation Status and Treatment Regimen

Supplementary Data from Multifunctional mRNA-Based CAR T Cells Display Promising Antitumor Activity Against Glioblastoma

Supplementary Data from Multifunctional mRNA-Based CAR T Cells Display Promising Antitumor Activity Against Glioblastoma

Supplementary Data from Prognostic Significance of DNA Methylation Profiles at MRI Enhancing Tumor Recurrence: a Report from the EORTC 26091 TAVAREC Trial

Supplementary Data from Prognostic Significance of DNA Methylation Profiles at MRI Enhancing Tumor Recurrence: a Report from the EORTC 26091 TAVAREC Trial

Supplementary Data from Temozolomide and Radiotherapy versus Radiotherapy Alone in Patients with Glioblastoma, <i>IDH</i>-wildtype: <i>Post Hoc</i> Analysis of the EORTC Randomized Phase III CATNON Trial

Supplementary Data from Temozolomide and Radiotherapy versus Radiotherapy Alone in Patients with Glioblastoma, <i>IDH</i>-wildtype: <i>Post Hoc</i> Analysis of the EORTC Randomized Phase III CATNON Trial

Supplementary Figure from Multifunctional mRNA-Based CAR T Cells Display Promising Antitumor Activity Against Glioblastoma

Supplementary Figure from Multifunctional mRNA-Based CAR T Cells Display Promising Antitumor Activity Against Glioblastoma

Supplementary Figure from Multifunctional mRNA-Based CAR T Cells Display Promising Antitumor Activity Against Glioblastoma

Supplementary Figure from Multifunctional mRNA-Based CAR T Cells Display Promising Antitumor Activity Against Glioblastoma

Supplementary Figure from Multifunctional mRNA-Based CAR T Cells Display Promising Antitumor Activity Against Glioblastoma

Supplementary Figure from Multifunctional mRNA-Based CAR T Cells Display Promising Antitumor Activity Against Glioblastoma

Supplementary Figure from Multifunctional mRNA-Based CAR T Cells Display Promising Antitumor Activity Against Glioblastoma

Supplementary Figure from Multifunctional mRNA-Based CAR T Cells Display Promising Antitumor Activity Against Glioblastoma

Supplementary Figure from Prognostic Significance of DNA Methylation Profiles at MRI Enhancing Tumor Recurrence: a Report from the EORTC 26091 TAVAREC Trial

Supplementary Figure from Prognostic Significance of DNA Methylation Profiles at MRI Enhancing Tumor Recurrence: a Report from the EORTC 26091 TAVAREC Trial

Supplementary Figure from Prognostic Significance of DNA Methylation Profiles at MRI Enhancing Tumor Recurrence: a Report from the EORTC 26091 TAVAREC Trial

Supplementary Figure from Prognostic Significance of DNA Methylation Profiles at MRI Enhancing Tumor Recurrence: a Report from the EORTC 26091 TAVAREC Trial

Supplementary Figure from Prognostic Significance of DNA Methylation Profiles at MRI Enhancing Tumor Recurrence: a Report from the EORTC 26091 TAVAREC Trial

Supplementary Figure from Prognostic Significance of DNA Methylation Profiles at MRI Enhancing Tumor Recurrence: a Report from the EORTC 26091 TAVAREC Trial

Supplementary Figure from Prognostic Significance of DNA Methylation Profiles at MRI Enhancing Tumor Recurrence: a Report from the EORTC 26091 TAVAREC Trial

Supplementary Figure from Prognostic Significance of DNA Methylation Profiles at MRI Enhancing Tumor Recurrence: a Report from the EORTC 26091 TAVAREC Trial

Supplementary Figure from Prognostic Significance of DNA Methylation Profiles at MRI Enhancing Tumor Recurrence: a Report from the EORTC 26091 TAVAREC Trial

Supplementary Figure from Prognostic Significance of DNA Methylation Profiles at MRI Enhancing Tumor Recurrence: a Report from the EORTC 26091 TAVAREC Trial

Supplementary Figure from Prognostic Significance of DNA Methylation Profiles at MRI Enhancing Tumor Recurrence: a Report from the EORTC 26091 TAVAREC Trial

Supplementary Figure from Temozolomide and Radiotherapy versus Radiotherapy Alone in Patients with Glioblastoma, <i>IDH</i>-wildtype: <i>Post Hoc</i> Analysis of the EORTC Randomized Phase III CATNON Trial

Supplementary Figure from Temozolomide and Radiotherapy versus Radiotherapy Alone in Patients with Glioblastoma, <i>IDH</i>-wildtype: <i>Post Hoc</i> Analysis of the EORTC Randomized Phase III CATNON Trial

Supplementary Figure from Temozolomide and Radiotherapy versus Radiotherapy Alone in Patients with Glioblastoma, <i>IDH</i>-wildtype: <i>Post Hoc</i> Analysis of the EORTC Randomized Phase III CATNON Trial

Supplementary Figure from Temozolomide and Radiotherapy versus Radiotherapy Alone in Patients with Glioblastoma, <i>IDH</i>-wildtype: <i>Post Hoc</i> Analysis of the EORTC Randomized Phase III CATNON Trial

Supplementary Figure from Temozolomide and Radiotherapy versus Radiotherapy Alone in Patients with Glioblastoma, <i>IDH</i>-wildtype: <i>Post Hoc</i> Analysis of the EORTC Randomized Phase III CATNON Trial

Supplementary Figure from Temozolomide and Radiotherapy versus Radiotherapy Alone in Patients with Glioblastoma, <i>IDH</i>-wildtype: <i>Post Hoc</i> Analysis of the EORTC Randomized Phase III CATNON Trial

Supplementary Figure from Temozolomide and Radiotherapy versus Radiotherapy Alone in Patients with Glioblastoma, <i>IDH</i>-wildtype: <i>Post Hoc</i> Analysis of the EORTC Randomized Phase III CATNON Trial

Supplementary Figure from Temozolomide and Radiotherapy versus Radiotherapy Alone in Patients with Glioblastoma, <i>IDH</i>-wildtype: <i>Post Hoc</i> Analysis of the EORTC Randomized Phase III CATNON Trial

Supplementary Figure from Temozolomide and Radiotherapy versus Radiotherapy Alone in Patients with Glioblastoma, <i>IDH</i>-wildtype: <i>Post Hoc</i> Analysis of the EORTC Randomized Phase III CATNON Trial

Supplementary Figure from Temozolomide and Radiotherapy versus Radiotherapy Alone in Patients with Glioblastoma, <i>IDH</i>-wildtype: <i>Post Hoc</i> Analysis of the EORTC Randomized Phase III CATNON Trial

Supplementary Figure from Temozolomide and Radiotherapy versus Radiotherapy Alone in Patients with Glioblastoma, <i>IDH</i>-wildtype: <i>Post Hoc</i> Analysis of the EORTC Randomized Phase III CATNON Trial

Supplementary Figure from Temozolomide and Radiotherapy versus Radiotherapy Alone in Patients with Glioblastoma, <i>IDH</i>-wildtype: <i>Post Hoc</i> Analysis of the EORTC Randomized Phase III CATNON Trial

Table S1 from The Epigenetic Evolution of Glioma Is Determined by the <i>IDH1</i> Mutation Status and Treatment Regimen

Table S2 from The Epigenetic Evolution of Glioma Is Determined by the <i>IDH1</i> Mutation Status and Treatment Regimen

Table S3 from The Epigenetic Evolution of Glioma Is Determined by the <i>IDH1</i> Mutation Status and Treatment Regimen

Table S3 from The Epigenetic Evolution of Glioma Is Determined by the <i>IDH1</i> Mutation Status and Treatment Regimen

Table S4 from The Epigenetic Evolution of Glioma Is Determined by the <i>IDH1</i> Mutation Status and Treatment Regimen

Table S4 from The Epigenetic Evolution of Glioma Is Determined by the <i>IDH1</i> Mutation Status and Treatment Regimen

Table S5 from The Epigenetic Evolution of Glioma Is Determined by the <i>IDH1</i> Mutation Status and Treatment Regimen

Table S5 from The Epigenetic Evolution of Glioma Is Determined by the <i>IDH1</i> Mutation Status and Treatment Regimen

Table S6 from The Epigenetic Evolution of Glioma Is Determined by the <i>IDH1</i> Mutation Status and Treatment Regimen

Table S6 from The Epigenetic Evolution of Glioma Is Determined by the <i>IDH1</i> Mutation Status and Treatment Regimen